Drug Search Results
More Filters [+]

Satavaptan

Alternative Names: satavaptan, sr121463b
Latest Update: 2023-08-24
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: V2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Satavaptan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Liver Cirrhosis|Inappropriate ADH Syndrome|Hyponatremia|Diabetes Insipidus|Heart Failure

Phase 2: Liver Cirrhosis|Hyponatremia|Inappropriate ADH Syndrome|Diabetes Insipidus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SPARe-2

P3

Completed

Liver Cirrhosis

2009-03-03

CATS

P3

Completed

Liver Cirrhosis

2008-12-30

PASCCAL-1

P2

Completed

Liver Cirrhosis

2008-12-03

AQUARIST1

P3

Terminated

Hyponatremia|Inappropriate ADH Syndrome

2008-12-01

Recent News Events